Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07767864 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum

Study acronym: BEAT-PG
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of the study is to learn more about an experimental drug bimekizumab that may be helpful for Pyoderma Gangrenosum (PG). Bimekizumab will be referred to as the study drug throughout this form. The investigators are hoping to find out if bimekizumab helps in healing PG wounds. The study drug is experimental. It has been approved by the FDA for use in adults with psoriatic conditions but not for Pyoderma Gangrenosum (PG).
Trial Details
NCT Number NCT07767864
Lead Sponsor Oregon Health and Science University
Collaborators: UCB Pharma
Conditions
(from sponsor)		 Pyoderma Gangrenosum
Related terms Pyoderma, Pyoderma Gangrenosum, Wounds and Injuries
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov